| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt, Anne Sauvaget, Marie-Alix Codet, Émeline Gaudré-Wattinne, Clotilde Wicart, Maud Rothärme. Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray. International journal of psychiatry in clinical practice. 2024-09-03. PMID:39223855. |
real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray. |
2024-09-03 |
2024-09-05 |
Not clear |
| Salman Hussain, Jafar Hayat, Hamad Almhanedi, Mohammad Alherz, Mahmoud Ebrahim, Ali Lari, Andrew Thambo. A Systematic Review and Meta-Analysis of Management Options for Empty Nose Syndrome: A Proposed Management Algorithm. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2024-08-10. PMID:39126290. |
empty nose syndrome (ens) is an acquired condition characterized by paradoxical nasal obstruction and sensation of nasal dryness often accompanied by psychological disorders such as depression or anxiety, typically occurring after the loss of inferior turbinate tissue or volume in the setting of prior sinonasal surgery. |
2024-08-10 |
2024-08-13 |
Not clear |
| Jorge Manuel Vásquez-Pérez, Edith González-Guevara, Diana Gutiérrez-Buenabad, Pablo Eliasib Martínez-Gopar, Juan Carlos Martinez-Lazcano, Graciela Cárdena. Is Nasal Dysbiosis a Required Component for Neuroinflammation in Major Depressive Disorder? Molecular neurobiology. 2024-08-09. PMID:39120823. |
human microbiota is known to influence immune and cerebral responses by direct and/or indirect mechanisms, including hypothalamic-pituitary-adrenal axis signaling, activation of neural afferent circuits to the brain, and by altering the peripheral immune responses (cellular and humoral immune function, circulatory inflammatory cells, and the production of several inflammatory mediators, such as cytokines, chemokines, and reactive oxygen species). the inflammatory responses in the nasal mucosa (rhinitis) or paranasal sinuses (chronic rhinosinusitis) are dual conditions related with a greater risk for developing depression. |
2024-08-09 |
2024-08-12 |
human |
| Jorge Manuel Vásquez-Pérez, Edith González-Guevara, Diana Gutiérrez-Buenabad, Pablo Eliasib Martínez-Gopar, Juan Carlos Martinez-Lazcano, Graciela Cárdena. Is Nasal Dysbiosis a Required Component for Neuroinflammation in Major Depressive Disorder? Molecular neurobiology. 2024-08-09. PMID:39120823. |
in this review, we discuss the role of microbiota-related immunity in conditions affecting the nasal mucosa (chronic rhinosinusitis and allergic rhinitis) and their relevance in major depressive disorders, focusing on the few mechanisms known to be involved and providing some hypothetical proposals on the pathophysiology of depression. |
2024-08-09 |
2024-08-12 |
human |
| Lisa Harding, Maryia Zhdanava, Aditi Shah, Jacqueline Pesa, Todor I Totev, Anabelle Tardif-Samson, Dominic Pilon, Kruti Josh. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray. Current medical research and opinion. 2024-07-22. PMID:39034772. |
understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray. |
2024-07-22 |
2024-07-24 |
human |
| Lisa Harding, Maryia Zhdanava, Aditi Shah, Jacqueline Pesa, Todor I Totev, Anabelle Tardif-Samson, Dominic Pilon, Kruti Josh. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray. Current medical research and opinion. 2024-07-22. PMID:39034772. |
this study aimed to characterize profiles and treatment history of patients with treatment-resistant depression (trd) who initiate esketamine nasal spray, by stringency of their health plans' pa criteria relative to the esketamine label. |
2024-07-22 |
2024-07-24 |
human |
| Adriano Bonura, Antonio Siniscalchi, Domenica Crupi, Alessandro Magliozzi, Maria Cristina Bravi, Mattia Internullo, Marilena Mangiardi, Francesca Romano Pezzella, Barbara Schito, Sabrina Anticol. Argyria and Neuropsychiatric Disorders: When not only the Matter is Gray. A Literature Review and a Case Report. Current medicinal chemistry. 2024-07-10. PMID:38984584. |
moreover, we report a case of a 50-year-old man admitted to our hospital with a diagnosis of major depression who presented with worsening psychiatric symptoms after abuse of silver-containing nasal spray. |
2024-07-10 |
2024-07-12 |
human |
| Roger S McIntyre, Istvan Bitter, Jozefien Buyze, Andrea Fagiolini, Yordan Godinov, Philip Gorwood, Tetsuro Ito, Albino J Oliveira-Maia, Eduard Vieta, Tamara Werner-Kiechle, Allan H Young, Andreas Rei. Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 85. 2024-07-02. PMID:38954874. |
safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. |
2024-07-02 |
2024-07-06 |
Not clear |
| Roger S McIntyre, Istvan Bitter, Jozefien Buyze, Andrea Fagiolini, Yordan Godinov, Philip Gorwood, Tetsuro Ito, Albino J Oliveira-Maia, Eduard Vieta, Tamara Werner-Kiechle, Allan H Young, Andreas Rei. Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 85. 2024-07-02. PMID:38954874. |
in escape-trd (nct04338321), esketamine nasal spray (ns) significantly increased the probability of remission at week 8, and of being relapse-free through week 32 after remission at week 8, versus quetiapine extended release (xr) in patients with treatment resistant depression (trd). |
2024-07-02 |
2024-07-06 |
Not clear |
| Petros Fotiadis, Eleni Tsalkitzi, Dimos Dimellis, Konstantinos Rantis, Athanasios Tsimpiris, Georgios Pagkalo. Results of esketamine administration in a Greek population: a case series. Psychiatrike = Psychiatriki. 2024-06-04. PMID:38814267. |
in 2019, the united states food and drug administration (fda) as well as the european medicines agency approved the use of esketamine nasal spray in combination with an oral antidepressant for treatment-resistant depression in adults. |
2024-06-04 |
2024-06-06 |
human |
| Lisa Harding, Kruti Joshi, Maryia Zhdanava, Aditi Shah, Arthur Voegel, Cindy Chen, Dominic Pilo. Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States. Drugs - real world outcomes. 2024-05-10. PMID:38727888. |
this study aimed to understand treatment patterns, acute healthcare use, and cost patterns among adults with treatment-resistant depression (trd) who completed induction treatment with esketamine nasal spray in the united states (us). |
2024-05-10 |
2024-05-27 |
Not clear |
| Kruti Joshi, Joshua N Liberman, Purva Parab, Jonathan D Darer, Lisa Hardin. Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression. The Journal of clinical psychiatry. vol 85. issue 2. 2024-05-09. PMID:38722197. |
barriers to esketamine nasal spray treatment among adults with treatment-resistant depression. |
2024-05-09 |
2024-05-27 |
Not clear |
| Kyoung Min Lee, Jung Hyo Rhim, Hyoung Jun Ahn, Martha Kim, Sohee Oh, Sun-Won Park, Seok Hwan Ki. Association between eyeball asymmetry and offset of openings in optic nerve head canal assessed by posterior polar eyeball topography. Scientific reports. vol 14. issue 1. 2024-04-30. PMID:38688983. |
eyeball asymmetry with focal bulging was determined by the existence of an adjacent outward protrusion/reciprocal inward depression pair, and the angular deviation of the outermost protruded point (opp) was measured from the nasal side of the fovea-bmo axis. |
2024-04-30 |
2024-05-03 |
human |
| Li-Yuan Zhao, Guang-Fen Zhang, Xue-Jie Lou, Kenji Hashimoto, Jian-Jun Yan. Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023. European archives of psychiatry and clinical neuroscience. 2024-04-25. PMID:38662093. |
in conclusion, this analysis revealed a significant increase in research on the antidepressant effects of ketamine and its enantiomers over the past two decades, leading to the approval of esketamine nasal spray for treatment-resistant depression. |
2024-04-25 |
2024-04-28 |
Not clear |
| Pia Baldinger-Melich, Marie Spies, Ina Bozic, Siegfried Kasper, Dan Rujescu, Richard Fre. Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy. Wiener klinische Wochenschrift. 2024-04-25. PMID:38662240. |
modern electroconvulsive therapy (ect) and the approval of nasal esketamine for clinical use have significantly improved the approach to treatment-resistant depression (trd), which is defined as non-response to at least two different courses of antidepressants with verified adherence to treatment, adequate dosage, and duration of treatment. |
2024-04-25 |
2024-04-28 |
Not clear |
| H Ubhi, A Ferro, C Ebelthite, K Fa. Predictive risk factors of adverse mental health outcomes in the facial trauma patient. International journal of oral and maxillofacial surgery. 2024-04-18. PMID:38637181. |
risk of ptsd was lower in zygomatic injuries (p = 0.001), while nasal involvement increased at-risk status for depression (p = 0.009). |
2024-04-18 |
2024-04-21 |
Not clear |
| Jennifer Kern Sliwa, Ronaldo R Naranjo, Ibrahim Turkoz, Mary Pat Petrillo, Patricia Cabrera, Madhukar Trivedi, Elizabeth Daloisi. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire. CNS spectrums. 2024-04-01. PMID:38557430. |
effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the montgomery-Åsberg depression rating scale and the 9-item patient health questionnaire. |
2024-04-01 |
2024-04-04 |
Not clear |
| Maud Rothärmel, Lila Mekaoui, François Kazour, Morgane Herrero, Eva-Maria Beetz-Lobono, Aiste Lengvenyte, Jérôme Holtzmann, Philippe Raynaud, Macarena Cuenca, Samuel Bulteau, Pierre de Maricourt, Thomas Husson, Emilie Olié, Bénédicte Gohier, Anne Sauvaget, Raphaël Gaillard, Raphaëlle Richieri, David Szekely, Ludovic Samalin, Olivier Guillin, Virginie Moulier, Wissam El-Hage, Andrew Laurin, Lucie Berkovitc. Esketamine-induced post-traumatic stress disorder flashbacks during treatment-resistant depression indication: is it just a side effect? medRxiv : the preprint server for health sciences. 2024-01-31. PMID:38293161. |
esketamine nasal spray is a recent validated treatment for treatment-resistant depression (trd), but its efficacy on comorbid trd-ptsd remains insufficiently documented. |
2024-01-31 |
2024-02-02 |
Not clear |
| Vanessa M McDonald, Yuto Hamada, Alvar Agusti, Peter G Gibso. Treatable Traits in Asthma: The importance of extra- pulmonary traits - GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety. The journal of allergy and clinical immunology. In practice. 2024-01-26. PMID:38278324. |
in this review we explore this concept and look at atopic dermatitis, chronic rhinosinusitis with nasal polyps (crswnp), gastroesophageal reflux disease, anxiety, and depression as treatable traits of asthma and how these can be managed using this approach. |
2024-01-26 |
2024-01-29 |
Not clear |
| Júlia Vendrell-Serres, Óscar Soto-Angona, Amanda Rodríguez-Urrutia, Benedetta Inzoli, Antonia López González, Josep Antoni Ramos-Quirog. Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 22. issue 1. 2024-01-22. PMID:38247422. |
treating treatment-resistant depression with esketamine nasal spray when all therapeutic options have been exhausted: clinical experience from a spanish cohort of expanded use. |
2024-01-22 |
2024-01-24 |
Not clear |